Adult-use cannabis policy stages linked to lower heroin involvement in…
From medical authorization to adult-use retail: Cannabis policy stages and heroin involvement among U.S. substance use treatment admissions.
AI Summary
This observational policy study asked whether heroin involvement differed across successive cannabis-policy stages among U.S. substance-use treatment admissions. It analyzed approximately 55.2 million admission records from 1992 through 2023, comparing state-year policy regimes with continued absence of a coded cannabis policy using a staggered-adoption difference-in-differences design. The primary outcome was heroin involvement among reported admissions—not heroin use in the general population.
In the primary equal-state analysis, heroin involvement was lower during adult-use legalization without operational retail and during operational adult-use retail than under continued no-policy status. The estimated differences were reported per 1,000 admissions; medical-policy stages showed no statistically significant heroin-related effects, and estimates for other opiates and synthetics were also not statistically significant. The later-stage heroin estimates remained negative but were attenuated and no longer statistically significant with equal-state-year weighting. Because this is an observational analysis of treatment admissions, it cannot establish that cannabis-policy changes caused the differences or that heroin use declined overall; this is an abstract-based summary.
💡 Key Findings
📄
Original Abstract
Related Research
Similar Studies
More Policy research papers you might find interesting.
Commentary finds retail trends cannot measure young adults’ personal cannabis…
Connecticut teens’ harm beliefs were linked to nicotine and cannabis use
Opioid policy associations differed by legal cannabis supply, but remain…
Explore More Research
Stay informed about the latest cannabis science.